Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cambrex Corp. (NYSE: CBM).

Full DD Report for CBM

You must become a subscriber to view this report.


Recent News from (NYSE: CBM)

Cambrex Completes Pilot Plant Expansion at its High Point, NC Facility
EAST RUTHERFORD, N.J., May 15, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed a pilot plant expansion at its High Point, NC facility wit...
Source: GlobeNewswire
Date: May, 15 2018 08:00
Cambrex's (CBM) CEO Steven Klosk on Q1 2018 Results - Earnings Call Transcript
Cambrex Corporation. (CBM) Q1 2018 Results Earnings Conference Call May 03, 2018, 08:30 AM ET Executives Tom Vadaketh - Executive Vice President and Chief Financial Officer Steve Klosk - President and Chief Executive Officer Analysts John Kreger - William Blair Drew Jones -...
Source: SeekingAlpha
Date: May, 04 2018 21:14
Cambrex misses by $0.05, beats on revenue
Cambrex (NYSE: CBM ): Q1 EPS of $0.37 misses by $0.05 . More news on: Cambrex Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 03 2018 06:49
Cambrex Reports First Quarter 2018 Financial Results
- Net Revenue increased 34% vs. prior year quarter, which includes a favorable impact from the adoption of ASC 606 - - 2018 full year financial guidance reaffirmed - - Conference call at 8:30 a.m. ET on May 3, 2018 - EAST RUTHERFORD, N.J., May 03, 2018 (GLOBE NEWSWIRE) -- Cambre...
Source: GlobeNewswire
Date: May, 03 2018 06:45
The Best Way To Invest In Pharma And Biotech?
"During the Gold Rush, most would-be miners lost money, but people who sold them picks, shovels, tents and blue-jeans (Levi Strauss) made a nice profit." - Peter Lynch Source Invest in Pharma/Biotech? As a medical student, I tend to dig a little deeper in my company research when I...
Source: SeekingAlpha
Date: April, 30 2018 14:00
Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem - Discovering Underlying Factors of Influence
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blackbaud, Inc. (NASDAQ:BLKB), Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS...
Source: GlobeNewswire
Date: April, 27 2018 07:35
Cambrex to Announce First Quarter 2018 Financial Results on May 3, 2018
EAST RUTHERFORD, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2018 financial results will be released on Thursday, May 3, 2...
Source: GlobeNewswire
Date: April, 26 2018 15:15
Cambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC Facility
EAST RUTHERFORD, N.J., April 23, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed the construction and validation of a new $3.2 million, 1...
Source: GlobeNewswire
Date: April, 23 2018 08:20
Cambrex Corporation to Provide Additional Information Regarding its Environmental, Social and Governance Practices
EAST RUTHERFORD, N.J., April 19, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide its stockholders with additional information regarding i...
Source: GlobeNewswire
Date: April, 19 2018 16:30
Cambrex Invests in New Continuous Flow Technology at its High Point, NC Facility
EAST RUTHERFORD, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed the installation of multiple continuous flow reactor pla...
Source: GlobeNewswire
Date: April, 17 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1748.0048.0048.2547.85315,608
2017-11-0848.9546.5049.2045.151,515,418
2017-11-0742.7549.4549.7542.751,213,949
2017-11-0644.1542.6544.7142.55742,749
2017-11-0343.6544.1545.9043.65415,609

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-151,9974,91640.6225Short
2018-08-143004,5446.6021Cover
2018-08-131909,3092.0410Cover
2018-08-103,61448,4737.4557Cover
2018-08-092,0415,05740.3599Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBM.


About Cambrex Corp. (NYSE: CBM)

Logo for Cambrex Corp. (NYSE: CBM)

Not available

 

Contact Information

 

 

Current Management

  • James A. Mack / CEO
  • Claes Glasell / President, COO
  • Salvatore Guccione / CFO
  • Peter E. Thauer / Secretary

Current Share Structure

  • Market Cap: $1,582,055,568 - 05/11/2018
  • Issue and Outstanding: 32,959,491 - 05/01/2018

 


Recent Filings from (NYSE: CBM)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 19 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 05 2018

 

 


Daily Technical Chart for (NYSE: CBM)

Daily Technical Chart for (NYSE: CBM)


Stay tuned for daily updates and more on (NYSE: CBM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: CBM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CBM and does not buy, sell, or trade any shares of CBM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/